John Wiley & Sons, Inc. (NYSE:WLYB - Get Free Report) shares were up 3.4% on Monday . The stock traded as high as $44.41 and last traded at $43.99. Approximately 15 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 680 shares. The stock had previously closed at $42.53.
John Wiley & Sons Stock Up 1.6 %
The firm has a 50-day moving average price of $43.13 and a two-hundred day moving average price of $44.93. The company has a market capitalization of $2.38 billion, a P/E ratio of -48.49 and a beta of 0.68. The company has a quick ratio of 0.61, a current ratio of 0.66 and a debt-to-equity ratio of 1.26.
John Wiley & Sons Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, April 24th. Shareholders of record on Tuesday, April 8th were given a $0.3525 dividend. The ex-dividend date was Tuesday, April 8th. This represents a $1.41 annualized dividend and a yield of 3.20%. John Wiley & Sons's dividend payout ratio is 190.54%.
About John Wiley & Sons
(
Get Free Report)
John Wiley & Sons, Inc engages in the provision of research and learning materials. It operates through the following segments: Research, Learning, and Held for Sale or Sold. The Research segment consists of research publishing and research solutions. The Learning segment includes academic and professional reporting lines and consists of publishing and related knowledge solutions.
Read More
Before you consider John Wiley & Sons, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and John Wiley & Sons wasn't on the list.
While John Wiley & Sons currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
